Holen Sie sich die Stockscreener-App
1.39
6.11%
0.08
Handel nachbörslich:
1.35
-0.04
-2.88%
Acrivon Therapeutics Inc Aktie (ACRV) Neueste Nachrichten
How to integrate Acrivon Therapeutics Inc. into portfolio analysis toolsWeekly Profit Report & Growth Focused Entry Reports - Newser
Short interest data insights for Acrivon Therapeutics Inc.2025 Year in Review & Stock Timing and Entry Methods - Newser
Why Acrivon Therapeutics Inc. is moving todayJuly 2025 PreEarnings & Capital Efficient Trading Techniques - Newser
Oppenheimer Adjusts Acrivon Therapeutics Price Target to $8 From $9, Maintains Outperform Rating - MarketScreener
Using fundamentals and technicals on Acrivon Therapeutics Inc.2025 Technical Overview & Reliable Volume Spike Alerts - Newser
Best data tools to analyze Acrivon Therapeutics Inc. stock2025 Retail Activity & Community Verified Swing Trade Signals - Newser
Is Acrivon Therapeutics Inc. stock a good hedge against inflationJuly 2025 Highlights & Verified Entry Point Signals - Newser
Why Acrivon Therapeutics Inc. stock attracts strong analyst attention2025 Market Trends & Weekly Market Pulse Updates - Newser
How Acrivon Therapeutics Inc. stock performs during market volatilityGap Up & Low Risk Entry Point Guides - Newser
Acrivon Therapeutics Reports Q2 2025 Financial Results - TipRanks
Acrivon Posts Narrower Loss in Q2 - Nasdaq
Acrivon Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights - GlobeNewswire
Acrivon's Cancer Drug Pipeline Advances with Tumor Response in Endometrial Cancer Trials - Stock Titan
Using economic indicators to assess Acrivon Therapeutics Inc. potentialEarnings Summary Report & High Yield Equity Trading Tips - Newser
Is Acrivon Therapeutics Inc. stock entering bullish territory2025 Volatility Report & Safe Entry Momentum Tips - Newser
Understanding Acrivon Therapeutics Inc.’s price movementMarket Weekly Review & High Conviction Buy Zone Picks - Newser
Published on: 2025-08-13 05:35:41 - Newser
Acrivon Therapeutics, Inc. Receives Buy Rating Due to Promising Clinical Data and Strategic Trial Expansion - TipRanks
Leading vs lagging indicators on Acrivon Therapeutics Inc. performanceDaily Trade Setup Forecast with Confidence - Newser
Real time alert setup for Acrivon Therapeutics Inc. performanceStable Profit Zone and Loss Control Analysis - Newser
Statistical indicators supporting Acrivon Therapeutics Inc.’s strengthFree Triple Digit Return Stock Predictions - Newser
Momentum divergence signals in Acrivon Therapeutics Inc. chartLoss Limitation Strategy Based on Analysis - Newser
How to recover losses in Acrivon Therapeutics Inc. stockFree AI Driven Stock Trend Forecast - Newser
Acrivon Therapeutics (ACRV) Expected to Announce Earnings on Tuesday - Defense World
What makes Acrivon Therapeutics Inc. stock price move sharplyTriple Digit Gain Opportunity Watchlist - Newser
Real time breakdown of Acrivon Therapeutics Inc. stock performanceAI Triggered Buy Zone Forecast System - Newser
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
How high can Acrivon Therapeutics Inc. stock price go in 2025Free Secure Return Focused Investment Plan - Newser
What moving averages say about Acrivon Therapeutics Inc.Early Entry Ideas with Momentum Potential - Newser
Tools to monitor Acrivon Therapeutics Inc. recovery probabilityFree Profit Target Stock Opportunity Monitor - Newser
Detecting support and resistance levels for Acrivon Therapeutics Inc.Trade Setup Builder with Custom Alerts - Newser
Will breakout in Acrivon Therapeutics Inc. lead to full recoveryRisk Balanced Picks for Safer Trading - Newser
Candlestick Reversal Detected on Acrivon Therapeutics Inc.’s ChartShort Term Buy Zone Stock Alerts Signal Entry - metal.it
Cantor Fitzgerald sets Acrivon stock to Overweight on AP3 platform - MSN
0.11%
1.56%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):